Haemonetics Corporation (market cap: $3.23B) reported its third-quarter earnings for fiscal year 2024, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $1.19, slightly ...
Mozart Therapeutics, the leading developer of CD8 Treg network modulators in autoimmune disease, announces the presentation of new preclinical data for MTX-201, a bispecific antibody that antagonizes ...